Our Science – Kreisl Website
Teri N. Kreisl, M.D.
Selected Publications |
 |
| 1)
Kreisl TN, Smith P, Sul J, Salgado C, Iwamoto FM, Shih JH, Fine HA. Continuous daily sunitinib for recurrent glioblastoma. J. Neurooncol. 111: 41-8, 2013. [Journal] |
|
| 2)
Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro-oncology. 14: 1519-26, 2012. [Journal] |
|
| 3)
Kreisl TN, Zhang W, Odia Y, Shih JH, Butman JA, Hammoud D, Iwamoto FM, Sul J, Fine HA. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-oncology. 13: 1143-50, 2011. [Journal] |
|
| 4)
Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J. Neurooncol. 105: 281-9, 2011. [Journal] |
|
| 5)
Lehky TJ, Iwamoto FM, Kreisl TN, Floeter MK, Fine HA. Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome. Neurology. 76: 236-41, 2011. [Journal] |
|
| 6)
Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D, Fine HA. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-oncology. 12: 181-9, 2010. [Journal] |
|
| 7)
Moustakas A, Kreisl TN. New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco Targets Ther. 3: 27-38, 2010. [Journal] |
|
| 8)
Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA. Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Cancer. 116: 1776-82, 2010. [Journal] |
|
| 9)
Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, Olsen Bailey N, Kreisl TN, Iwamoto FM, Sul J, Auh S, Park GE, Fine HA, Black PM. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J. Clin. Oncol. 28: 3838-43, 2010. [Journal] |
|
| 10)
Kreisl TN, Kim L, Moore K, Duic P, Kotliarova S, Walling J, Musib L, Thornton D, Albert PS, Fine HA. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin. Cancer Res. 15: 3617-23, 2009. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/16/2013.
